311 related articles for article (PubMed ID: 30783189)
1. Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.
Recio C; Guerra B; Guerra-Rodríguez M; Aranda-Tavío H; Martín-Rodríguez P; de Mirecki-Garrido M; Brito-Casillas Y; García-Castellano JM; Estévez-Braun A; Fernández-Pérez L
Oncogene; 2019 Jun; 38(24):4657-4668. PubMed ID: 30783189
[TBL] [Abstract][Full Text] [Related]
2. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
3. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
4. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
5. SFK-STAT pathway: an alternative and important way to malignancies.
Hayakawa F; Naoe T
Ann N Y Acad Sci; 2006 Nov; 1086():213-22. PubMed ID: 17185518
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.
Hennighausen L; Robinson GW
Genes Dev; 2008 Mar; 22(6):711-21. PubMed ID: 18347089
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
8. STAT5 signaling in normal and pathologic hematopoiesis.
Bunting KD
Front Biosci; 2007 May; 12():2807-20. PubMed ID: 17485261
[TBL] [Abstract][Full Text] [Related]
9. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
Cai B; Cai JP; Luo YL; Chen C; Zhang S
Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
[TBL] [Abstract][Full Text] [Related]
10. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
[TBL] [Abstract][Full Text] [Related]
13. STAT5 and STAT5 Inhibitors in Hematological Malignancies.
Tolomeo M; Meli M; Grimaudo S
Anticancer Agents Med Chem; 2019; 19(17):2036-2046. PubMed ID: 31490767
[TBL] [Abstract][Full Text] [Related]
14. The identification and characterization of a STAT5 gene signature in hematologic malignancies.
Sonkin D; Palmer M; Rong X; Horrigan K; Regnier CH; Fanton C; Holash J; Pinzon-Ortiz M; Squires M; Sirulnik A; Radimerski T; Schlegel R; Morrissey M; Cao ZA
Cancer Biomark; 2015; 15(1):79-87. PubMed ID: 25524945
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells.
Sandoval-Usme MC; Umaña-Pérez A; Guerra B; Hernández-Perera O; García-Castellano JM; Fernández-Pérez L; Sánchez-Gómez M
PLoS One; 2014; 9(1):e87769. PubMed ID: 24489959
[TBL] [Abstract][Full Text] [Related]
16. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
17. An insight into JAK-STAT signalling in dermatology.
Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
[TBL] [Abstract][Full Text] [Related]
18. Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins.
Gutiérrez-Hoya A; Soto-Cruz I
Cells; 2020 Oct; 9(10):. PubMed ID: 33076315
[TBL] [Abstract][Full Text] [Related]
19. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.
Groner B; von Manstein V
Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744
[TBL] [Abstract][Full Text] [Related]
20. The potential and controversy of targeting STAT family members in cancer.
Verhoeven Y; Tilborghs S; Jacobs J; De Waele J; Quatannens D; Deben C; Prenen H; Pauwels P; Trinh XB; Wouters A; Smits ELJ; Lardon F; van Dam PA
Semin Cancer Biol; 2020 Feb; 60():41-56. PubMed ID: 31605750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
